Back to Cancer Australia's website

Cancer Australia

Select a guideline

Follow up of women with epithelial ovarian cancer


1. National Breast and Ovarian Cancer Centre. Follow-up of women with epithelial ovarian cancer: a systematic review. National Breast and Ovarian Cancer Centre, Surry Hills, NSW, 2012.

2. Australian Institute of Health and Welfare & National Breast and Ovarian Cancer Centre. Ovarian cancer in Australia: an overview, 2010. Cancer series no. 52. Cat. no. CAN 48. AIHW, Canberra, 2010.

3. Jordens C, Morrell B, Harnett P, et al. Cancergazing? CA125 and post-treatment surveillance in advanced ovarian cancer. Social Science & Medicine. 2010;71(9):1548-56.

4. Gu P, Pan L, Wu S, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164-74.

5. Gadducci A and Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Critical Reviews in Oncology/Hematology 2009;71(1):43–52.

6. Gadducci A, Cosio S, Zola P, et al. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2007;17(1):21-31.

7. Hall M and Rustin G. Recurrent Ovarian Cancer: When and How to Treat. Curr Oncol Rep. 2011;13(6):459-71.

8. Kew F, Galaal K, Manderville H and Verleye L. Professionals' and patients' views of routine follow-up: a questionnaire survey. Int J Gynecol Cancer. 2007;17(3):557-560.

9. Ersek M, Ferrell BR, Dow KH and Melancon C. Quality of life in women with ovarian cancer. West J Nurs Res. 1997;19(3):334-350.

10. Howell D, Fitch ML and Deane KA. Impact of ovarian cancer perceived by women. Cancer Nur. 2003;26(1):1-9.

11. Palmer C, Pratt J, Basu B and Earl H. A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference. Gynecol Oncol. 2006;101(1):4-11.

12. Cox A, Bull E, Cockle-Hearne J, et al. Nurse led telephone follow up in ovarian cancer: a psychosocial perspective. Eur J Oncol Nurs. 2008;12(5):412-7.

13. Wenzel LB, Donnelly JP, Fowler JM, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncoogy group study. Psycho Oncology. 2002;11(2):142-53.

14. National Breast and Ovarian Cancer Centre. Multidisciplinary care principles for advanced disease: a guide for cancer health professionals. National Breast and Ovarian Cancer Centre, Surry Hills, NSW, 2008.

15. BC Cancer Agency. Accessed: September 2010.

16. Chan KK, Tam KF, Tse KY and Ngan HY. The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecol Oncol. 2008;110(2):158-61.

17. Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. International Journal of Gynecological Cancer. 2009;19(3):367-74.

18. Gibb R, Brooks RA, Rosenblum K, et al. Patterns of postoperative surveillance for ovarian cancer: What we do and why we do it. Gynecol Oncol. 2006;101(Issue 1 Supplement 1):S108.

19. National Comprehensive Cancer Centre (NCCN). NCCN Clinical Practice Guidelines in Oncology-Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer 2009.

20. Von Georgi R, Schubert K, Grant P and Munstedt K. Post-therapy surveillance and after-care in ovarian cancer. European Journal of Obstetrics Gynecology and Reproductive Biology. 2004;114(2):228-233.

21. Fehm T, Heller F, Kramer S, et al. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Research. 2005;25(3 A):1551-1554.

22. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155-63.

23. Morris RT and Monk BJ. Ovarian cancer: relevant therapy, not timing, is paramount. Lancet. 2010;376(9747):1120-1122.

24. Society of Gynecologic Oncologists. Society of Gynecologic Oncologists Statement on Use of CA125 for Monitoring Ovarian Cancer. Society of Gynecologic Oncologists, SGO, 2009.

25. Verheijen RHM, Cibula D, Zola P and Reed N. Cancer Anitgen 125: lost to follow-up? A European Society of Gynaecological Oncology Consensus Statement. Int J Gynecol Cancer. 2012;22(1):170-74.

26. Oksefjell H, Sandstad B and TropĂƒ© C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol. 2009;20(2):286-93.

27. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100(6):1152-61.

28. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289-95.

29. Kew F, Galaal K, Bryant A and Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database of Systematic Reviews. 2011;Issue 6(CD006119):1-25.

Published using CeCC Docbook Manager